Priming phase Effector phase MHC

First Page		Document Content
Date: 2014-01-24 11:51:27 Immune system Ipilimumab PD-1 Cancer vaccine PD-L1 Cancer immunotherapy CTLA-4 Melanoma Immunotherapy Medicine Immunology Biology		Priming phase Effector phase MHC Add to Reading List Source URL: www.onclive.com Download Document from Source Website File Size: 3,38 MB Share Document on Facebook

	# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,,#, Stephen M. Shaw 1,, Kim Wi DocID: 1vdls - View Document
	Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx DocID: 1uTyz - View Document
	FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy Program DocID: 1tGAn - View Document
	Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer Lab DocID: 1tBVB - View Document